semaglutide

Pharma

BMO says Lilly is pulling ahead of Novo in obesity market battle

Eli Lilly has caught up to Novo Nordisk, says BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indiana company.

Kevin Dunleavy Apr 17, 2025 4:30pm

Novo charts $1B-plus Brazilian production expansion for GLP-1s

Apr 8, 2025 9:40am

Novo's oral GLP-1 Rybelsus cuts heart disease risks

Mar 31, 2025 11:30am

Texas judge allows Novo Nordisk to intervene in compounders suit

Mar 6, 2025 8:45am

FDA faces new lawsuit from compounders over weight loss drugs

Feb 25, 2025 10:56am

Novo Nordisk's semaglutide shortage officially resolved in US

Feb 21, 2025 11:08am